Merck won a favorable European committee recommendation for KEYTRUDA plus Padcev as perioperative treatment, expanding its potential European market for bladder cancer; final EU approval is expected by Q4 2026.
The EMA committee recommended Keytruda plus Padcev for perioperative use, which broadens Merck's potential EU market for bladder cancer. Strong Phase 3 results and an earlier U.S. clearance support lasting sales upside, though the European Commission must still grant final approval expected by Q4 2026.
Pfizer was a partner on the Phase 3 KEYNOTE-B15 study that underpins the recommendation, supporting Pfizer's role in the combination's commercial opportunity; the European Commission will decide by Q4 2026.
Follow Merck & Co., Inc. (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRK